A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

← catalyst calendar

NCT06920901 · readout ≤ 42 d

Sponsored by Apogee Therapeutics, Inc. (industry) · APGE — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

31actual

Sites

Countries

United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-03-27

actual

When the study began enrolling

Primary completion

Sep 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2027

estimated

The whole study's end, after follow-up

First posted

2025-04-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Asthma

Interventions

Drug: APG777
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment Emergent Adverse Events (TEAEs)

measured Up to 52 weeks

Number of Participants with Abnormal Laboratory Findings

measured Up to 52 weeks

Number of Participants with Abnormal Vital Signs

measured Up to 52 weeks

Number of Participants with Abnormal Electrocardiograms (ECGs)

measured Up to 52 weeks

Number of Participants with Abnormal Physical Examination Findings

measured Up to 52 weeks

Publications

PMID 41422501 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · APGE's whole pipeline · Catalyst calendar · Every registered study · What changed